OBJECTIVE: Sequence variation in gene promoters is often associated with disease risk. We tested the hypothesis that common promoter variation in the APOH gene (encoding for ss(2)-glycoprotein I) is associated with systemic lupus erythematosus (SLE) risk and SLE-related clinical phenotypes in a Caucasian cohort. METHODS: We used a case-control design and genotyped 345 women with SLE and 454 healthy control women for 8 APOH promoter single-nucleotide polymorphisms (SNP; -1284C>G, -1219G>A, -1190G>C, -759A>G, -700C>A, -643T>C, -38G>A, and -32C>A).Association analyses were performed on single SNP and haplotypes. Haplotype analyses were performed using EH (Estimate Haplotype-frequencies) and Haploview programs. In vitro reporter gene assay was performed in COS-1 cells. Electrophoretic mobility shift assay (EMSA) was performed using HepG2 nuclear cells. RESULTS: Overall haplotype distribution of the APOH promoter SNP was significantly different between cases and controls (p = 0.009). The -643C allele was found to be protective against carotid plaque formation (adjusted OR 0.37, p = 0.013) among patients with SLE. The -643C allele was associated with a ~2-fold decrease in promoter activity as compared to wild-type -643T allele (mean +/- standard deviation: 3.94 +/- 0.05 vs 6.99 +/- 0.68, p = 0.016). EMSA showed that the -643T>C SNP harbors a binding site for a nuclear factor. The -1219G>A SNP showed a significant association with the risk of lupus nephritis (age-adjusted OR 0.36, p = 0.016). CONCLUSION: Our data indicate that APOH promoter variants may be involved in the etiology of SLE, especially the risk for autoimmune-mediated cardiovascular disease.
OBJECTIVE: Sequence variation in gene promoters is often associated with disease risk. We tested the hypothesis that common promoter variation in the APOH gene (encoding for ss(2)-glycoprotein I) is associated with systemic lupus erythematosus (SLE) risk and SLE-related clinical phenotypes in a Caucasian cohort. METHODS: We used a case-control design and genotyped 345 women with SLE and 454 healthy control women for 8 APOH promoter single-nucleotide polymorphisms (SNP; -1284C>G, -1219G>A, -1190G>C, -759A>G, -700C>A, -643T>C, -38G>A, and -32C>A).Association analyses were performed on single SNP and haplotypes. Haplotype analyses were performed using EH (Estimate Haplotype-frequencies) and Haploview programs. In vitro reporter gene assay was performed in COS-1 cells. Electrophoretic mobility shift assay (EMSA) was performed using HepG2 nuclear cells. RESULTS: Overall haplotype distribution of the APOH promoter SNP was significantly different between cases and controls (p = 0.009). The -643C allele was found to be protective against carotid plaque formation (adjusted OR 0.37, p = 0.013) among patients with SLE. The -643C allele was associated with a ~2-fold decrease in promoter activity as compared to wild-type -643T allele (mean +/- standard deviation: 3.94 +/- 0.05 vs 6.99 +/- 0.68, p = 0.016). EMSA showed that the -643T>C SNP harbors a binding site for a nuclear factor. The -1219G>A SNP showed a significant association with the risk of lupus nephritis (age-adjusted OR 0.36, p = 0.016). CONCLUSION: Our data indicate that APOH promoter variants may be involved in the etiology of SLE, especially the risk for autoimmune-mediated cardiovascular disease.
Authors: Bastiaan Hoogendoorn; Sharon L Coleman; Carol A Guy; Kaye Smith; Tim Bowen; Paul R Buckland; Michael C O'Donovan Journal: Hum Mol Genet Date: 2003-07-22 Impact factor: 6.150
Authors: Haider Mehdi; Susan Manzi; Purnima Desai; Qi Chen; Cara Nestlerode; Franklin Bontempo; Stephen C Strom; Reza Zarnegar; M Ilyas Kamboh Journal: Eur J Biochem Date: 2003-01
Authors: G Aleph Prieto; Antonio R Cabral; Martín Zapata-Zuñiga; Abraham J Simón; Antonio R Villa; Donato Alarcón-Segovia; Javier Cabiedes Journal: Arthritis Rheum Date: 2003-02
Authors: Faith Selzer; Kim Sutton-Tyrrell; Shirley G Fitzgerald; Joan E Pratt; Russell P Tracy; Lewis H Kuller; Susan Manzi Journal: Arthritis Rheum Date: 2004-01
Authors: Qi Chen; Steven E Reis; Candace Kammerer; Wendy Y Craig; Sue E LaPierre; Erin Luedecking Zimmer; Dennis M McNamara; Daniel F Pauly; Barry Sharaf; Richard Holubkov; C Noel Bairey Merz; George Sopko; Franklin Bontempo; M Ilyas Kamboh Journal: Circulation Date: 2003-06-16 Impact factor: 29.690
Authors: F Yesim K Demirci; Amy S Dressen; Candace M Kammerer; M Michael Barmada; Amy H Kao; Rosalind Ramsey-Goldman; Susan Manzi; M Ilyas Kamboh Journal: J Rheumatol Date: 2011-01-15 Impact factor: 4.666
Authors: Karin Bolin; Johanna K Sandling; Agneta Zickert; Andreas Jönsen; Christopher Sjöwall; Elisabet Svenungsson; Anders A Bengtsson; Maija-Leena Eloranta; Lars Rönnblom; Ann-Christine Syvänen; Iva Gunnarsson; Gunnel Nordmark Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240